Complementation by Wild-type P53 of Interleukin-6 Effects on M1 Cells: Induction of Cell Cycle Exit and Cooperativity with C-myc Suppression
Overview
Authors
Affiliations
Stable transfection of M1 myeloid leukemia cells with a temperature-sensitive mutant of p53 results in two phenomena that are manifested exclusively at the permissive temperature. On one hand, activation of wild-type p53 by the temperature shift induced an apoptotic type of cell death which could be inhibited by interleukin-6 (IL-6) (E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren, Nature 352:345-347, 1991). On the other hand, as reported in this work, activated p53 complemented the antiproliferative effects of IL-6 in M1 cells. A shift to the permissive temperature concomitant with or early after IL-6 treatment imposed a novel pattern of cell cycle arrest in which about 95% of the cells were retained within a G0-like quiescent state. This phase was characterized by 2N DNA content and low RNA and protein content. On the molecular level, activation of wild-type p53 transrepressed the c-myc gene but not the cyclin A, D1, or D2 gene, which are all independently suppressed by IL-6 in M1 cells. To further analyze whether c-myc inhibition mediates or complements p53 effects, the p53-transfected M1 cells were infected with a retroviral vector expressing deregulated c-myc, refractory to p53 or IL-6 action. It was found that the process of cell death was not interrupted at all in these M1 c-myc-p53 double transfectants, suggesting that the transrepression of c-myc is not a major obligatory event mediating p53-induced cell death. In addition, some of the antiproliferative effects of activated p53, manifested in the presence of IL-6, could still be transmitted in the background of constitutive c-myc. Yet the context of deregulated c-myc interfered with the final accumulation of cells within a G0-like phase, suggesting complementary interactions between the outcome of p53 activation and of c-myc suppression in the control of cell cycle arrest.
Hamada A, Kita Y, Sakatani T, Nakamura K, Takada H, Ikeuchi R Oncogene. 2025; .
PMID: 39987272 DOI: 10.1038/s41388-025-03311-5.
Yang X, Bai Z, He Y, Wang N, Sun L, Li Y BMC Plant Biol. 2024; 24(1):312.
PMID: 38649800 PMC: 11036760. DOI: 10.1186/s12870-024-04985-x.
Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression.
Ogunleye A, Nimmakayala R, Batra S, Ponnusamy M Stem Cells. 2023; 41(5):417-430.
PMID: 36869789 PMC: 10183971. DOI: 10.1093/stmcls/sxad017.
Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.
Almeida J, Mota I, Skoda J, Sousa E, Cidade H, Saraiva L Cancers (Basel). 2022; 14(24).
PMID: 36551697 PMC: 9777536. DOI: 10.3390/cancers14246212.
Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.
Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee Y JCI Insight. 2022; 7(23).
PMID: 36301668 PMC: 9746918. DOI: 10.1172/jci.insight.160130.